Navigation Links
Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
Date:3/28/2011

le myeloma following treatment with at least three prior therapies.  Patients are being randomized to receive carfilzomib (20mg/m2 on days 1 and 2 of cycle 1 only, then 27mg/m2 subsequently).   The primary endpoint is overall survival with secondary endpoints including PFS, overall response rate (ORR), clinical benefit rate (CBR) and duration of response (DOR), as well as safety.  The study design incorporates planned interim analyses on the primary endpoint.

Onyx on Track for Submission of NDA in the U.S.  

In January, Onyx announced that the U.S. Food and Drug Administration (FDA) had granted fast track designation for carfilzomib.  Onyx has initiated a rolling submission of a New Drug Application (NDA) for potential accelerated approval of carfilzomib in the U.S. Through the Fast Track designation, Onyx is eligible to submit the carfilzomib NDA on a rolling basis, allowing Onyx to begin the NDA filing process immediately and giving the FDA an opportunity to review the completed sections of the registration application. Onyx has now submitted the non-clinical section of the carfilzomib NDA with the FDA and commenced its rolling NDA process. Onyx intends to complete its submission of the NDA for potential accelerated approval of carfilzomib in the U.S. as early as mid-2011.

About the Carfilzomib Development Program

The carfilzomib development program includes a large, randomized international Phase 3 clinical trial, known as the ASPIRE trial, studying the combination of lenalidomide and low dose dexamethasone with or without carfilzomib in patients with relapsed multiple myeloma. The company has an agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) and received Scientific Advice from the European Medicines Agency (EMA) on the design and planned analysis of the ASPIRE trial.  Carfilzomib is also being evaluated in a broad investigator sponsored tria
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
2. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
3. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
4. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
5. Endo Pharmaceuticals Appoints Dr. David Nash to Board of Directors
6. Cempra Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
7. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
8. MAP Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results on March 4, 2011
11. Anthera Pharmaceuticals to Present at the Citi 2011 Global Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bed bug cases tend to increase during summer. And ... risk of becoming the pests' next victim throughout the season, ... the guide, the company enumerated the steps of getting ... , According to My Cleaning Products, there are two ... during summer: the warm weather and the rise in travel. ...
(Date:5/24/2013)... Many factors impact tissues targeting such as ... at the blood-tissue barrier. Even when tissue disposition is ... the tissue rather than the total tissue concentration. , ... to guide lead optimization, predict in vivo activity in ... may impact the likely human clinical dose. , In ...
(Date:5/23/2013)... , May 24, 2013 ... angefertigt – Bei der englischen ... , 91 % der Teilnehmer einer groß angelegten ... 20 % laut GINA [*] -Definition [1] als ... Menschen mit Asthma generell einer von vier Denkweisen zugeordnet ...
(Date:5/23/2013)... MD (PRWEB) May 23, 2013 Can ... off from work motivate members of the public to ... researchers including Johns Hopkins Carey Business School ... emphatic yes. Pointing to a large body of recent ... in the May 24, 2013, issue of Science that ...
Breaking Biology Technology:Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 2Steps for Getting Rid of Bed Bugs without Using Chemicals and Avoiding Them While Traveling Enumerated by My Cleaning Products in Its Latest Post 3DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... be misleading to suggest that scientists at UW-Madison or anywhere ... fact, no scientist in the state has even announced plans ... to suggest the process for cloning a human embryo for ... from the process used in therapeutic cloning. The first step ...
... or wife, daughter or son, sister or brother? , ,No, ... I've just been thinking about the IT/business relationship. When I ... it's funny how frequently the conversation turns to communication, mutual ... great!" you're thinking. "Now you want me to get yelled ...
... - MyWeather LLC has named Kevin Baird ... , ,Baird went to Carleton College and began his ... Martin Schreiber. He has served as vice resident of ... technology company; vice president of sales and marketing for ...
Cached Biology Technology:The Attack of the Clones: No, its not a summer movie 2The Attack of the Clones: No, its not a summer movie 3Taking your work home 2Taking your work home 3
(Date:5/24/2013)... to combat metastatic cancer , Cancer cells spread ... immune system. Stimulation of the immune system can help ... that cause the immune system to ignore cancer cells. ... suppress the immune system response. In this issue of ... by Ronald Levy at Stanford University found that regulatory ...
(Date:5/24/2013)... years, microRNAs (miRNAs) and other non-coding RNAs are ... specific proteins. In recent years they have emerged ... to establish tissue origin for cancers of unknown ... screen for disease, but clinically tractable, diagnostic methods ... not currently available. In this issue of the ...
(Date:5/24/2013)... In the search for medication against Alzheimer,s disease, scientists have ... break down Amyloid beta (A-beta). After all, it is the ... brains of Alzheimer,s patients. Starting point for the formation of ... were the first to unravel the function of APPL ... healthy fruit flies. , Alessia Soldano (VIB/KU Leuven): "We ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
... at the Virginia Bioinformatics Institute (VBI) at Virginia Tech has ... to infect plants and cause disease. The discovery paves the ... plant, and even some animal cells, from deadly fungal infections. ... the journal Cell . The researchers have ...
... the Finnish Forest Research Institute, Metla, "feel relaxed and good ... us know that there is also scientific evidence about the ... natural, green settings can reduce stress, improve moods, reduce ... also strengthen our immune system by increasing the activity and ...
... This release is also available in Chinese ... known as angiogenesis, is crucial for sustained tumor growth ... the growth of these vessels have been available to ... and quantification of blood vessel growth using nonsurgical methods ...
Cached Biology News:Scientists discover how deadly fungal microbes enter host cells 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 2Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents 3
Request Info...
... 0 (or Cap 0-like) RNA into Cap ... been shown to increase in vivo translation ... is seen in Cap 0 structures created ... well as those Cap 0 structures created ...
Form: Ready to use Applications: ELISA...
RABBIT ANTI HALOPERIDOL...
Biology Products: